May 24, 2025 a 07:43 pm
EW: Fundamental Ratio Analysis - Edwards Lifesciences Corporation
Edwards Lifesciences Corporation operates in a vital area of healthcare, focusing on solutions for structural heart disease and critical care monitoring. Its comprehensive product line, including minimally invasive valve replacement technologies, places it at the forefront of medical device innovation. With its headquarters in Irvine, California, the company continues to expand its international reach.
Fundamental Rating
The current fundamental rating for Edwards Lifesciences Corporation is moderate. Below is a breakdown of key financial metrics and their scores.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 3 | |
| Return on Equity | 1 | |
| Return on Assets | 1 | |
| Debt to Equity | 1 | |
| Price to Earnings | 2 | |
| Price to Book | 1 |
Historical Rating
The historical performance indicates a consistent pattern in fundamental scores. Below are past and current ratings for comparison.
| Date | Overall | DCF | ROE | ROA |
|---|---|---|---|---|
| 2025-05-23 | 1 | 3 | 1 | 1 |
Analyst Price Targets
Analyst price targets suggest a positive outlook, with a consensus lean towards a moderate growth potential.
| High | Low | Median | Consensus |
|---|---|---|---|
| $90 | $74 | $76.5 | $79.25 |
Analyst Sentiment
Analyst sentiment remains favorable, with a substantial number of 'Buy' ratings over 'Hold' recommendations.
| Recommendation | Count | Distribution |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 28 | |
| Hold | 17 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Edwards Lifesciences Corporation displays a balanced investment outlook, especially given its innovative approach within the healthcare sector. While fundamental scores reflect moderate financial health, analyst price targets indicate optimism in the stock's potential growth. The consensus 'Buy' recommendations suggest a strong market confidence in its operational strategies. However, potential investors should remain mindful of stock volatility and sector-specific risks associated with medical device companies. Overall, Edwards Lifesciences appears to be a solid long-term investment with promising returns.